Citadel Advisors’s Aoxing Pharmaceutical Company Inc. AXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-61,329
| Closed | -$10K | – | 8817 |
|
|
2017
Q3 | $10K | Buy |
+61,329
| New | +$16.7K | ﹤0.01% | 7438 |
|
|
2017
Q1 | – | Sell |
-63,789
| Closed | -$20K | – | 8432 |
|
|
2016
Q4 | $20K | Buy |
63,789
+53,621
| +527% | +$22.2K | ﹤0.01% | 7094 |
|
|
2016
Q3 | $6K | Sell |
10,168
-10,156
| -50% | -$6.83K | ﹤0.01% | 7156 |
|
|
2016
Q2 | $13K | Sell |
20,324
-4,946
| -20% | -$3.35K | ﹤0.01% | 6707 |
|
|
2016
Q1 | $17K | Buy |
25,270
+7,966
| +46% | +$5.88K | ﹤0.01% | 6526 |
|
|
2015
Q4 | $12K | Buy |
+17,304
| New | +$21.7K | ﹤0.01% | 8223 |
|
|
2015
Q1 | – | Sell |
-21,347
| Closed | -$7K | – | 9064 |
|
|
2014
Q4 | $7K | Sell |
21,347
-16,267
| -43% | -$4.38K | ﹤0.01% | 8219 |
|
|
2014
Q3 | $8K | Buy |
37,614
+11,136
| +42% | +$3.53K | ﹤0.01% | 7821 |
|
|
2014
Q2 | $8K | Sell |
26,478
-7,354
| -22% | -$2.87K | ﹤0.01% | 7639 |
|
|
2014
Q1 | $14K | Sell |
33,832
-19,079
| -36% | -$6.81K | ﹤0.01% | 7418 |
|
|
2013
Q4 | $13K | Sell |
52,911
-538
| -1% | -$142 | ﹤0.01% | 6653 |
|
|
2013
Q3 | $14K | Buy |
+53,449
| New | +$13.1K | ﹤0.01% | 6381 |
|
Citadel Advisors's AXN Position: Q4 2017 in Review
Citadel Advisors sold out of Aoxing Pharmaceutical Company Inc. (AXN) in Q4 2017, closing a stake of 61,329 shares — an estimated $10K sold.
Citadel Advisors first reported a position in AXN in Q3 2013 and held it in 12 quarters. The position peaked at $20K in Q4 2016. 0 funds tracked by Wall St. Rank hold AXN as of Q4 2017.
- Citadel Advisors reported no remaining Aoxing Pharmaceutical Company Inc. position as of Q4 2017 after selling out during the quarter.
- Citadel Advisors sold 61,329 Aoxing Pharmaceutical Company Inc. shares in Q4 2017, an estimated $10K.
- Citadel Advisors first reported a position in Aoxing Pharmaceutical Company Inc. in Q3 2013 and held it in 12 quarters.
- Citadel Advisors's Aoxing Pharmaceutical Company Inc. position peaked at $20K in Q4 2016.
- 0 funds tracked by Wall St. Rank held Aoxing Pharmaceutical Company Inc. as of Q4 2017.
Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.